Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD By Ogkologos - November 7, 2025 127 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Retifanlimab Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard Therapy in Patients with HR-positive, HER2-positive MBC FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma MOST POPULAR Ribociclib Approval Expanded for Some Women with Advanced Breast Cancer August 20, 2018 EMA Recommends to Extend the Indications for Tislelizumab May 8, 2025 Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible... November 18, 2024 Does Living Near Power Lines Increase My Risk of Cancer? March 17, 2022 Load more HOT NEWS High School Students Put Together Fundraiser for Teacher Diagnosed with Breast... A peek behind the scenes: Just how are our funding decisions... Best Friends and Owners of a Specialty Cheese Shop Battle Breast... More Evidence that One HPV Vaccine Dose Protects against Cancer-Causing Infections
